Home InterMune

InterMune

acquired
Post-IPO Round
Pulmonology, Orphan Fibrosis Disease Therapy Research, Developer
Basic
Enterprise Profile

Basic Information

InterMune Focuses on Research and Development of Innovative Therapies for Pulmonology and Orphan Fibrotic Diseases. In the field of pulmonology, InterMune concentrates on treatments for Idiopathic Pulmonary Fibrosis (IPF), a progressive and fatal lung disease.
InterMune, Inc.
SanFrancisco,California,United States of America
101~500 people
January 01, 1998
ir@intermune.com

Enterprise Profile

Industrial Sector
New Drug Development Biological Drug Production
Technology
Biotechnology
Concept
Respiratory Diseases Therapeutic Products
Application Scenarios
Innovative Drugs